Insmed (INSM) Interest Expenses (2011 - 2026)
Insmed (INSM) posted quarterly Interest Expenses of $20.1 million for Q1 2026, down 6.89% year-over-year from $21.6 million in Q1 2025, and up 194.87% quarter-over-quarter from -$21.2 million in Q4 2025.
Insmed (INSM) Interest Expenses (2011 - 2026) Analysis & Trends
Insmed's Interest Expenses history runs 16 years deep, the most recent figure standing at $20.1 million for Q1 2026.
- In Q1 2026, Interest Expenses fell 6.89% year-over-year to $20.1 million; the TTM figure through Mar 2026 stood at $40.5 million (down 52.55% YoY), while the FY2025 annual figure was $1.5 billion, up 29.44% from the prior year.
- Interest Expenses for Q1 2026 stood at $20.1 million, up from -$21.2 million in the prior quarter.
- The five-year high for Interest Expenses was $21.6 million in Q1 2025, with the low at -$21.2 million in Q4 2025.
- The 5-year median for Interest Expenses is $20.3 million (2023), against an average of $14.3 million.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses soared 514.21% in 2023, then plunged 198.23% in 2025.
- Insmed's Interest Expenses stood at $16.4 million in 2022, then tumbled by 49.37% to $8.3 million in 2023, then soared by 158.83% to $21.6 million in 2024, then slumped by 198.23% to -$21.2 million in 2025, then surged by 194.87% to $20.1 million in 2026.
- Business Quant data shows INSM's Interest Expenses at $20.1 million in Q1 2026, -$21.2 million in Q4 2025, and $20.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.27 Mn |
| Jun 30, 2026 | 20.27 Mn |
| Mar 31, 2026 | 20.08 Mn |
| Mar 31, 2026 | 20.08 Mn |
| Dec 31, 2025 | -21.17 Mn |
| Dec 31, 2025 | -21.17 Mn |
| Sep 30, 2025 | 20.38 Mn |
| Sep 30, 2025 | 20.38 Mn |
| Jun 30, 2025 | 21.25 Mn |
| Jun 30, 2025 | 21.25 Mn |
| Mar 31, 2025 | 21.57 Mn |
| Mar 31, 2025 | 21.57 Mn |
| Dec 31, 2024 | 21.55 Mn |
| Dec 31, 2024 | 21.55 Mn |
| Sep 30, 2024 | 21.05 Mn |
| Sep 30, 2024 | 21.05 Mn |
| Jun 30, 2024 | 21.27 Mn |
| Jun 30, 2024 | 21.27 Mn |
| Mar 31, 2024 | 21.04 Mn |
| Mar 31, 2024 | 21.04 Mn |